Shilpa Medicare's Q1 FY 2026-27 Quarterly Results

Result Summary

• Shilpa Medicare Ltd reported a 6.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 43.0%.
• Its expenses for the quarter were up by 4.2% QoQ and 35.8% YoY.
• The net profit decreased 6.4% QoQ and increased 115.1% YoY.
• The earnings per share (EPS) of Shilpa Medicare Ltd stood at 5.16 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Shilpa Medicare Ltd is a pharmaceutical company engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs) and formulations. It operates within the pharmaceutical industry, primarily focusing on oncology, peptides, and biologics sectors. The company has been involved in various innovative projects and has a presence in both domestic and international markets. As of the latest data provided, there are no specific recent developments mentioned. The company is known for its commitment to quality and compliance with international health standards.

Revenue

For Q1FY27, Shilpa Medicare Ltd reported a total income of ₹468.91 crores. This reflects a quarter-over-quarter (QoQ) growth of 6.9% from ₹438.66 crores in Q4FY26. Year-over-year (YoY), the company experienced a significant increase in total income, rising by 43.0% from ₹327.84 crores in Q1FY26. This substantial growth indicates a strong upward trend in revenue generation over the year. The consistent rise in revenue highlights the company's ability to enhance its market presence and expand its product offerings or market reach.

Profitability

The company's profitability metrics for Q1FY27 show a Profit Before Tax (PBT) of ₹92.09 crores, which is a decline of 9.8% QoQ from ₹102.13 crores reported in Q4FY26. However, when compared YoY, there is an impressive increase of 83.0% from ₹50.31 crores in Q1FY26. The Profit After Tax (PAT) for the same quarter stands at ₹100.88 crores, marking a 6.4% decrease QoQ from ₹107.79 crores in Q4FY26, yet showing a remarkable 115.1% increase YoY from ₹46.89 crores in Q1FY26. These figures suggest a significant improvement in profitability over the year despite a slight QoQ decline. Earnings per share (EPS) for Q1FY27 is ₹5.16, down 6.4% from ₹5.51 in the previous quarter, with a YoY increase of 7.7% from ₹4.79.

Operating Metrics

Total expenses for Q1FY27 amounted to ₹376.82 crores, which is a 4.2% increase from ₹361.55 crores in Q4FY26. Compared to Q1FY26, total expenses rose by 35.8% from ₹277.52 crores, reflecting a growing scale of operations. The tax impact for Q1FY27 shows a negative value of ₹-2.83 crores, contrasting with a positive ₹12.66 crores in Q4FY26 and ₹2.69 crores in Q1FY26. This anomaly in tax figures might affect the overall financial outlook for the period. The financial ratios and detailed balance sheet items such as P/E ratio, debt-to-equity ratio, or current ratio were not provided in the data, hence, specific calculations on these metrics could not be performed.